CliffBio
small molecule

AMPYRA

DALFAMPRIDINE

Loss of exclusivity—loss of exclusivity
CompanyMerz Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMPYRA
Active ingredientDALFAMPRIDINE
Strength10MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2010
Marketing statusRX

More from Merz Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AMPYRA patent cliff — loss of exclusivity — | CliffBio